Applied DNA Sciences Relocates Corporate Headquarters to New York
News Dec 20, 2005
This relocation coincides with a restructuring of the Company's board and management team, including the appointment of James A. Hayward, Ph.D., Sc.D., as CEO. Dr. Hayward founded The Collaborative Group of biotechnology companies.
Dr. Hayward, whose Ph.D. in molecular biology was awarded by SBU in 1983, also received an honorary Doctor of Science degree from SBU in 2000.
Dr. Hayward stated, "Applied DNA's relocation to Long Island is a critical step in our commercial operation. The Company is commercializing a pipeline of opportunities that will be our focus in 2006."
"We are establishing a prototyping laboratory at Stony Brook to customize the products already validated last year in association with the Department of Energy and our scientific group in Biowell Taiwan. Biowell's scientists have already begun their relocation to Stony Brook."
Dr. Yacov Shamash, Vice President of Economic Development for SBU and Dean of the College of Engineering said, "We are pleased to welcome APDN as the newest member of our community."
"We are confident about the value of the Company's technology pipeline, the abilities of the new management team and the ability of the incubator program to facilitate the Company's growth."
"The excellent combination of molecular biology and security technology offered by APDN is a natural addition to the University's role in combining engineering with science to launch new business and is a good example of the kind of the product development that will flow from the new Center of Excellence in Wireless and Information Technology."
APDN is the newest member of Long Island's life science community comprised of institutional and business scientists.
Joseph Scaduto, Director of the Long Island Life Sciences Initiative of which Dr. Hayward is Chair, stated, "Long Island is one of the nation's epicenters for leading research in DNA technologies."
"It is an ideal location for the scientists of APDN to work in a highly dynamic and interactive environment."
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE